(8S,9S,10S,13R,14S,17S)-17-ethyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,3-diol | 26445-07-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8S,9S,10S,13R,14S,17S)-17-ethyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,3-diol
• CAS: 26445-07-8
• 化学式: C₂₁H₃₆O₂
• 分子量: 320.5
• InChiKey: JBSVQUOGNMYMSF-CIQUAOMQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Steroid derivatives,processes for their preparation and pharmaceutical compositions thereof
  申请人：RICHTER GEDEON VEGYESZETI GYAR R.T.

  公开号：EP0387090A2

  公开（公告）日：1990-09-12

  The invention relates to novel Δ¹⁴-16α,17-dihydroxy-pregnane-16,17-cyclic aldehyde acetal and -cyclic ketone ketal derivatives of general formula (I), wherein A stands for hydrogen or hydroxyl group; X stands for hydrogen or halogen with the proviso that if A is hydrogen, then X also means hydrogen; R stands for hydrogen,benzoyl or C₁⁻₈alkanoyl group; R¹ and R², which are the same or different, stand for hydrogen or a C₁⁻₄alkyl group; or one of R¹ and R² is hydrogen and the other is phenyl group; or R¹ and R² together form a C₄⁻₅alkylene group; --- means a single or double bond between two adjacent carbon atoms, as well as pharmaceutical compositions containing these compounds and a process for their preparation. The compounds of general formula (I) possess a very strong antiinflammatory effect and only week harmful side effect. Thus, they can be used as active ingredients of antiinflammatory pharmaceutical compositions being useful in the therapy.

  本发明涉及通式（I）的新型Δ¹⁴-16α,17-二羟基孕甾烷-16,17-环醛缩醛和-环酮缩酮衍生物、 其中 A 代表氢或羟基； X 代表氢或卤素，但如果 A 是氢，则 X 也代表氢； R 代表氢、苯甲酰基或 C₁-₈ 烷酰基； R¹ 和 R²（相同或不同）代表氢或 C₁-₄ 烷基；或 R¹ 和 R² 中的一个是氢，另一个是苯基；或 R¹ 和 R² 共同形成 C₄-₅ 烯基； ----指两个相邻碳原子之间的单键或双键、 以及含有这些化合物的药物组合物及其制备方法。 通式（I）的化合物具有很强的抗炎作用，只有一周的有害副作用。因此，它们可用作抗炎药物组合物的活性成分，在治疗中非常有用。
• Steroid diols, processes for their preparation and pharmaceutical compositions thereof
  申请人：RICHTER GEDEON VEGYESZETI GYAR R.T.

  公开号：EP0387091A2

  公开（公告）日：1990-09-12

  The invention relates to Δ¹⁴-16α,17-dihydroxypregnane derivatives of general formula (I), wherein A represents a hydrogen atom, or hydroxyl or trifluoroacetoxy group; X represents a hydrogen or halogen atom with the proviso that if A is a hydrogen atom, X is also a hydrogen atom; R represents a hydrogen atom, a benzoyl or C₁₋₈ alkanoyl group; and --- represents a single or double bond between the two adjacent carbon atoms, as well as pharmaceutical compositions containing these compounds and a process for their preparation. The compounds of general formula (I) possess valuable antiinflammatory effects and thus may be used as active ingredients in antiinflammatory pharmaceutical compositions. They may also be useful in the preparation of other therapeutically useful steroid derivatives.

  本发明涉及通式（I）的Δ¹⁴-16α,17-二羟基孕甾烷衍生物、 其中 A 代表氢原子、羟基或三氟乙酰氧基； X 代表氢原子或卤素原子，但有以下条件 如果 A 是氢原子，X 也是氢原子； R 代表氢原子、苯甲酰基或 C₁₋₈ 烷酰基； 和 --- 代表相邻两个碳原子之间的单键或双键、 以及含有这些化合物的药物组合物及其制备方法。 通式（I）化合物具有重要的抗炎作用，因此可用作抗炎药物组合物的活性成分。它们还可用于制备其他具有治疗作用的类固醇衍生物。
• Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
  申请人：Global Genomics Group, LLC

  公开号：US10254272B2

  公开（公告）日：2019-04-09

  The invention, in some aspects, relates to methods for evaluating a human subject for having atherosclerotic coronary artery disease (ASCAD) or as having a coronary atherosclerotic plaque. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling and treating atherosclerotic CAD and or a coronary atherosclerotic plaque.

  在某些方面，本发明涉及评估人体是否患有冠状动脉粥样硬化性疾病（ASCAD）或冠状动脉粥样硬化斑块的方法。在某些方面，本发明涉及用于诊断、分类、剖析和治疗动脉粥样硬化性冠状动脉疾病和或冠状动脉粥样硬化斑块的方法和试剂盒。
• Process for the preparation of 16,17 acetals of pregnane derivatives with control of the epimeric distribution at the C-22 position
  申请人：Farmabios S.p.A.

  公开号：EP0875516B1

  公开（公告）日：2005-10-12
• NOVEL 17ß-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
  申请人：The Regents of the University of California

  公开号：EP2736919A2

  公开（公告）日：2014-06-04